IRRAS Launches Next-Generation of the IRRAflow System in the United States

• The next-generation IRRAflow control unit has been designed to continue to enhance the procedural workflow for health care professionals treating critically ill patients suffering from intracranial bleeds.
• The upgrades that have been made to the IRRAflow control unit and its software to improve the overall user experience include interactive tutorials, intuitive software with upgraded graphics, refined treatment workflow, and a new drainage collection design.

Stockholm, February 22, 2022 – IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced the commercial launch of its next-generation IRRAflow system, the company’s latest innovation to advance the treatment of intracranial bleeding, in the United States. This next-generation technology is continued validation of the company’s commitment to providing an enhanced user experience while treating critically ill patients.

The IRRAflow system offers advanced fluid management to therapeutically treat critically ill patients with intracranial bleeding by incorporating recurring irrigation that dilutes collected toxic material, making it easier to remove, and prevents solid particles from blocking drainage holes, ensuring that fluid can continuously be drained throughout the entire treatment. IRRAflow’s combination of automated irrigation and controlled drainage results in fewer complications and more through drainage. 

The launch of the next-generation IRRAflow control unit will now enhance the user experience by providing:

• Step-by-step interactive tutorials to guide system setup,
• Additional data tracking to help nursing better assess the patient’s condition each hour of treatment,
• An intuitive graphical user interface that simplifies treatment workflow and adjustment of treatment parameters, and
• A new drainage collection design that provides additional options to optimize fluid drainage. 

Click on the link https://www.youtube.com/watch?v=2P7aV4-b4XI to experience the next-generation IRRAflow system

The first next-generation IRRAflow systems have been shipped to initial customer locations in the US, and staff training is now underway, with first patient treatments expected in the near future.

"Since our IRRAflow system was launched in the US, our team has worked closely with our customers to assess how we can further improve our products to improve the outcomes for our critically ill patients,” said Will Martin, President and Chief Executive Officer of IRRAS. “Our team has taken that feedback and has incorporated it into the next generation of our IRRAflow system. The customer response thus far confirms that the upgrades that have been made to the system will enhance the user experience, shorten training time required, and improve our ability to support patient treatments remotely.  Each of these factors will continue to significantly improve patient outcomes and contribute to continued sales growth.”

About IRRAS

IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.

IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS).

For more information, please contact:

Sten Gustafsson
Director, Investor Relations
sten.gustafsson@irras.com
+46 102 11 5172

The information was released for public disclosure, through the agency of the contact person above, on February 22, 2022, at 8:30 (CET).